Total antioxidant status in type 2 diabetes mellitus with diabetic nephropathy
DOI:
https://doi.org/10.18203/2349-3933.ijam20191540Keywords:
Diabetic nephropathy, Microalbuminuria, Oxidative stress, Total antioxidant statusAbstract
Background: Diabetes mellitus has emerged as one of the most common health hazard all over the world. Diabetic nephropathy is the most challenging long term complication of Type 2 Diabetes mellitus and microalbuminuria is the earliest marker of diabetic nephropathy. In diabetes, chronic hyperglycemia and deranged lipid profile lead to excess generation of free radicals. The increased oxidative stress plays a major role in pathogenesis of diabetic complications, including diabetic nephropathy. There are many naturally occurring antioxidant enzymes in our body. Diabetes has multiple effects on protein levels and activity of these antioxidant enzymes. This further augments the oxidative stress. There are many non-enzymatic antioxidants in our body which include vitamins A, C, E and trace minerals like copper, zinc, manganese and selenium.
Methods: The study was done on a total of 150 subjects. Group A comprised of 60 Type 2 diabetic patients with diabetic nephropathy, Group B comprised of 60 Type 2 diabetic patients without diabetic nephropathy and Group C comprised 30 healthy controls. Total antioxidant status, microalbuminuria and glycosylated haemoglobin were measured.
Results: In present study, authors found that total antioxidant status is drastically reduced in all diabetic patients, and it was found to be further low in patients with diabetic nephropathy. This decrease was found to be directly proportional to the degree of diabetic nephropathy, as measured by the levels of microalbuminuria.
Conclusions: Timely institution of antioxidant supplementation therapy may emerge as a promising measure in delaying the onset and progression of diabetic complications, especially diabetic nephropathy.
References
Kraiser AB, Zhang N, Van Der Pluijm W. Global Prevalence of Type 2 Diabetes over the Next Ten Years. Diabetes. 2018;67(1).
India Today Web Desk New Delhi November 22, 2018. Available at: https://www. India today. in
Huizinga MM, Rothman RL. Addressing the diabetes pandemic: A comprehensive approach. Indian J Med Res. 2006 Nov 1;124(5):481.
Epidemiology of kidney disease in United States. United States Renal Data System. National Institute of Health, National Institute of diabetes, digestive and kidney diseases. USRDS annual data report. Bethesda. 2014:188-210.
Rani CS, Rema M, Deepa R, Premlatha G, Ravikumar R, Mohan A et al. The Chennai Urban Population Study-methodological details. Int J Diab Develop Countries. 1999;19:149-55.
Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diab. 1995;44(11):1303-9.
Unnikrishnan R, Rema M, Pradeepa R, Deepa M, Deepa R, Mohan V. Prevalence and risk factors of diabetic nephropathy in urban South Indian Population. The Chennai Urban Rural Epidemiology Study (CURES 45). Diab Care. 2007;30(8):2019-24.
Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress and antioxidants: A review. J Biochem Mol Toxicol. 2003;17(1):24-38.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599-622.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diab. 2003;52(1):1-8.
Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotte‐taylor KR, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Annals of the New York Acad Sci. 2001;947(1):214-23.
Vega- Lopez S, Devraj S, Jialal L. Oxidative stress and anti-oxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med. 2004;52(1):24-32.
Peuchant E, Delmas MCB, Couchouran A. Short term insulin therapy and normoglycemia. Effects on erythrocytes lipid peroxidation in NIDDM patients. Diab Care. 1997;20(2):202-7.
Bagchi K, Puri S.Free radicals and anti-oxidants in Health and Disease. Eastern Mediterranean Health J. 1998;4:350-60.
Vasavada N, Agarwal R. Role of oxidative stress in diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12(2):146-54.
Samuel V, Johney S. Lipid peroxidation in diabetic nephropathy. Pharma. Sci Res. 2011;3(2):1046-51.
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diab. 1983;32(2):64-78.
Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Internal Med. 1991 Sep 1;151(9):1761-5.
Lehman R, Spinas GA. Diabetic nephropathy: significance of microalbuminuria in type 1 and type 2 diabetes. Kidney Int. 1994;51:20-3.
Dinneen SF, Gerstein HC. The as sociation of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Internal Medicine. 1997157(13):1413-8.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-6.
Mokdad AH, Ford ES, Bowman BA. Prevalence of obesity, diabetes and obesity related health risk factors. JAMA. 2003;289:76-9.
Shaukat A, Arian TM, Shahid A. Microalbuminuria: Incidence in patients of diabetes at Bhawalpur. Pak J Pathol. 2005;16(1):17-21.
Brownlee M, Hirsch IB. Glycemic variability: Haemoglobin A1c- an independent risk factor for diabetic complications. JAMA. 2006;295(14):1707-8.
American Diabetes Association. Diabetic Nephropathy. Diab Care. 20002;25(1):585-9.
Miller NJ, Rice-Evans CA. Factors influencing the antioxidant activity determined by the ABTS•+ radical cation assay. Free Radical Res. 1997;26(3):195-9.
Smart D, McCusker CA, Lamont JV. Reference values for various anti- oxidant parameters in a normal working population. Poster session (Poster B-548) at 16th International Congress of Clinical Chemistry; London; 1996 July.
Gomes MB, Luchhetti MR, Gonclaves MFR, Gazzolla H, Dimetz T, Matos H. Principal of microalbuminuria measurement by Nycocard. Braz J Med Biol Res. 1997;30(2):191-6.
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. Diabetologia. 1989 Apr 1;32(4):219-26.
Jeppson JO. Approved IFCC Reference Method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002;40(1):78-89.
American Diabetes Association. Diagnosis and the Classification of Diabetes Mellitus. Diab Care. 2011;34(1):S62-S69.
Bhatia S, Shukla R, Madhu SV, Gambhir JK, Prabhu KM. Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin Biochem. 2003;36(7):557-62.
Sheikh SA, Baig JA, Iqbal T, Kazmi T, Baig M, Hussain SS. Prevalence of microalbuminuria with relation to glycemic control in Type 2 diabetic patients in Karachi. J. Ayub Med Coll Abbottabad. 2009;21(3):1-17.
